Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Hypoxia activates the PI3K/AKT/HIF-1α pathway to promote the anti-inflammatory effect of adipose mesenchymal stem cells.

Ren H., Liu M., Jihu Y., Zeng H., Yao C., Yan H.

Laboratory Study on Chronic Inflammation, published in Acta Histochem (2023) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Acta Histochem (2023)
Country
Germany
Reported sample size
—
Source database
PubMed
PMID
37137202
DOI
10.1016/j.acthis.2023.152042
Citations
7

Abstract (original English)

This study aimed to investigate the effect of hypoxia on the anti-inflammatory effect of adipose-derived mesenchymal stem cells (AMSCs) in vitro and its possible mechanism. AMSCs were cultured in vitro in a hypoxic environment with 3% O 2 , and a normoxic (21% O 2 ) environment was used as the control. The cells were identified by in vitro adipogenic and osteogenic differentiation and cell surface antigen detection, and the cell viability were detected. The effect of hypoxic AMSCs on macrophage inflammation was analyzed by co-culture. The results showed that under hypoxia, AMSCs had better viability, significantly downregulated the expression of inflammatory factors, alleviated macrophage inflammation, and activated the PI3K/AKT/HIF-1α pathway.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansCell HypoxiaHypoxiaHypoxia-Inducible Factor 1, alpha SubunitInflammationMesenchymal Stem CellsObesityOsteogenesisPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-akt

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research